We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Allergy Therapeutics Plc | LSE:AGY | London | Ordinary Share | GB00B02LCQ05 | ORD 0.1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.025 | -0.86% | 2.875 | 2.75 | 3.00 | 3.10 | 2.875 | 2.95 | 759,943 | 11:42:05 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 59.59M | -43.07M | -0.0090 | -3.19 | 136.8M |
From May 2019 to May 2024
TIDMAGY
RNS Number : 1591W
Allergy Therapeutics PLC
05 November 2014
5 November 2014
Allergy Therapeutics plc
("Allergy Therapeutics" or "the Company")
Grant of Options
Allergy Therapeutics plc (AIM: AGY) announces that, pursuant to the Allergy Therapeutics plc Long Term Share Incentive Plan ('LTIP'), on 5 November 2014 provisional shares of 0.1 pence each in the share capital of the Company were awarded to the following Board Directors: Mr Manuel Llobet (Chief Executive Officer) and Mr Ian Postlethwaite (Finance Director) at nil cost, as follows:
Hot Features
Premium
Director Number of provisional Date of distribution Total provisional
shares awarded shares held under
LTIPs
4 November
Manuel Llobet 845,000 2014 3,315,000
---------------------- --------------------- -------------------
4 November
Ian Postlethwaite 422,500 2014 1,657,500
---------------------- --------------------- -------------------
The issuance and distribution of ordinary shares of 0.1 pence each under the LTIP is conditional on the Company's performance over the course of three years. The new Long Term Incentive Plan was adopted by the Board on 20 March 2013.
-Ends-
For further information
Allergy Therapeutics +44 (0) 1903 845 820 Manuel Llobet, Chief Executive Officer Ian Postlethwaite, Finance Director www.allergytherapeutics.com Peel Hunt LLP +44 (0) 20 7418 8900 James Steel / Clare Terlouw FTI Consulting +44 (0) 20 3727 1000 Simon Conway/ Mo Noonan / Victoria Foster Mitchell
Notes to editors
About Allergy Therapeutics
Allergy Therapeutics is a specialty pharmaceutical company focused on allergy vaccination. It has a growing business with revenue of GBP42million achieved mainly in Europe through its own sales and marketing infrastructure and further afield through distributors.
This information is provided by RNS
The company news service from the London Stock Exchange
END
RDSBIBDBCXGBGSS
1 Year Allergy Therapeutics Chart |
1 Month Allergy Therapeutics Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
